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ABSTRACT
As human spaceflight seeks to expand beyond low-Earth orbit, NASA and its international partners face numerous challenges
related to ensuring the safety of their astronauts, including the need to provide a safe and effective pharmacy for long-duration
spaceflight. Historical missions have relied upon frequent resupply of onboard pharmaceuticals; as a result, there has been
little study into the effects of long-term exposure of pharmaceuticals to the space environment. Of particular concern are the
long-term effects of space radiation on drug stability, especially as missions venture away from the protective proximity of the
Earth. Here we highlight the risk of space radiation to pharmaceuticals during exploration spaceflight, identifying the limitations
of current understanding. We further seek to identify ways in which these limitations could be addressed through dedicated
research efforts aimed towards the rapid development of an effective pharmacy for future spaceflight endeavors.
Introduction
With the expansion of human spaceflight outside of low-Earth
orbit (LEO), NASA and its international partners face numer-
ous challenges related to ensuring the safety of their astro-
nauts. Among these challenges is the ability to provide a safe
and effective pharmacy with sufficient capability to manage
both planned and unforeseen medical conditions that may
arise during flight. The ability to provide a safe and effec-
tive pharmacy to crews is contingent upon multiple factors,
such as the stability of any medication for the duration of
a given mission, the effectiveness of that medication in the
unique space environment, and the provision of appropriate
and sufficient medications to meet the unique physiological
and psychological challenges the crew may face.
There is a paucity of evidence regarding pharmaceutical
stability in the space environment, largely because this issue
has not historically been a pressing concern for human space-
flight. Short-duration flights of the Mercury, Gemini, Apollo,
and Space Shuttle eras minimized the need for prolonged
medication shelf life, and the selection of healthy crewmem-
bers minimized the need for ongoing medication provision
for chronic disease. Careful maintenance of crew health and
stringent flight rules regarding the more dangerous activities
during spaceflight, such as extravehicular activity (EVA), have
largely obviated the need for emergency medication provision.
Even now, with missions to the International Space Station
(ISS) lasting 6 months or longer, crews have been able to
rely on medication availability through retirement of expired
medications and frequent resupply rather than contending
with questions of degradation, storage, and the impact of the
space environment (with environmental concerns related to
a myriad of factors such as vibration, humidity, and space
radiation exposure). As a result, investments in the systematic
collection of data for the characterization of medication use,
efficacy, side effects, pharmacokinetics, pharmacodynamics,
and long-term stability have been a lower priority than other
health and human performance investments. With the push for
exploration missions to the moon and Mars, these questions
have become a more pressing concern.
One potential risk to pharmaceutical stability arises from
long-term exposure to the space radiation environment. While
gamma radiation exposure has been used terrestrially for ster-
ilization procedures in select pharmaceuticals, space radiation
differs considerably from such practices because of differ-
ences in type of radiation, dose, dose-rate, and length of
exposure. It is unclear whether long-term exposure to space
radiation may affect stability, alter drug ingredients, or pro-
duce potentially toxic byproducts, particularly in drugs that
have undergone degradation reactions.
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Here, we seek to present the current understanding of phar-
maceutical stability in the space radiation environment. In
particular, we have attempted to highlight the gaps in current
knowledge and the difficulties in translating terrestrial-based
radiation studies to a meaningful interpretation of drug re-
sponse to space radiation. We hope to identify high-yield
opportunities for future research that might better define and
mitigate the space radiation risk to a future formulary for
exploration spaceflight.
The Interplanetary Space Radiation Envi-
ronment
The effects of radiation are due to the transfer of energy from
a charged particle to the medium it travels through. The
amount of energy that can be transferred is a function of the
particle’s kinetic energy, charge, and mass.1, 2 The effects of
indirect ionizing radiation (e.g. gamma, x-ray) are negliglible
compared to effects caused by direct ionizing charged particle
risk. The more charge a particle has the greater ability it has
to ionize the medium it traverses, depositing more energy per
unit path length (defined as increased linear energy transfer,
or LET) in a traversed material.
Future space exploration endeavors will include manned ex-
peditions beyond the protection of the Earth’s magnetic field.
These long-duration missions, which may span months to
years, will require additional protection for the human crews
on board. The space radiation environment is a complex mix
of charged particles originating from several sources. Within
an exploration vehicle (one intended to travel outside of the
Earth’s geomagnetic field), the the intravehicular radiation
environment primarily consists of relativistic heavy-charged
particles attributed to galactic cosmic rays (GCR, chronic,
isotropic background radiation). The GCR spectrum, and thus
the intravehicular radiation environment, primarily consists
of ionized hydrogen (protons, approximately 85%) and he-
lium (alpha, approximately 14%) nuclei, but also includes
less abundant ionized particles of higher atomic weight.3, 4
Despite their rarity, heavier particles contribute a dispropor-
tionately high amount of overall radiation dose-exposure due
to their relatively high LET. In addition, as GCR ions pass
through vehicular structures, interaction with vehicle materi-
als can cause fragmentation (or ”spallation”) of heavier ions
into more numerous particles of lower atomic weight. This
process can produce cascades of ions resulting in a destructive
capability in addition to that of the primary ions. Accounting
for all such interactions increases the complexity of predicting
the intravehicular radiation environment. It is particularly
difficult to shield from GCR exposures given the isotropic,
highly penetrating nature, and the relative energies of the GCR
spectra.5
An additional, off-nominal source of charged particle radia-
tion can be attributed to solar particle events (SPEs), where
particles are ejected from the sun in prompt and short-lived
bursts of energy. SPEs consist primarily of protons and elec-
trons with a relatively small contribution from heavy nuclei.
Unlike GCR, SPEs are anisotropic.6 SPE radiation is pri-
marily composed of protons with kinetic energies ranging
from 10 MeV up to several GeV (determined by the rela-
tivistic speed of particles).3 SPEs are capable of accelerating
an abundance of protons that can occasionally result in high
dose-rates in the interplanetary environment. For example, a
particularly large event in October 1989 is predicted to have
delivered dose-rates as high as 1,454mGy/hour for a short pe-
riod of time to an exposed astronaut in a vehicle with 5g/cm2
of aluminum-equivalent shielding traveling in interplanetary
space.3, 7 While rare, SPE exposure would be in addition to
the nominal intravehicular dose, attributed to GCR nuclei,
expected to be approximately 0.028mGy/hour during travel
in interplanetary space.4 Interplanetary intravehicular doses
would be altered by the peak flux, energy spectrum, and du-
ration of any given SPE as well as shielding thickness and
material makeup of the vehicle. Similarly, the contribution of
radiation exposure from SPEs and resultant effects on phar-
maceuticals would depend upon intravehicular dose and any
additional shielding.
As missions to the moon or Mars will expand human pres-
ence from LEO to interplanetary space, intravehicular radia-
tion exposure will increase. Vehicles, and the pharmaceuticals
on board, will be exposed to higher cumulative GCR exposure
and increased risk for transient SPE exposures. As a result,
the risk of radiation-induced alterations of pharmaceutical sta-
bility, structure, potency, and potential toxicity will increase
with future missions (Figure 1).
Mechanisms of Radiation Impact
A majority of pharmaceutical radiation risk research is derived
from terrestrial analogs rather than the full particle and energy
spectrum of the space radiation environment. Accordingly,
differences in the relative abilities of terrestrial and space
radiation to induce damage in a target have yet to be elucidated.
This property of different types of radiation to induce different
levels and kinds of damage is known as radiation quality.
Radiation quality is thought to be dependent on LET, which
can be characterized by energy deposition pattern. Charged
particles traverse a material in an approximately straight line,
transferring energy through interactions with the medium’s
nuclei and electrons. Imparted energy may be enough to
knock an electron out of an atom, ionizing the atom or leaving
it in an excited, non-ionized state. The ejected electron can
have enough energy to leave the immediate vicinity of the
charged particle’s path and produce a notable track of its
own. This results in a densely ionizing core along the charged
particle’s path (where energy continues to be deposited in an
approximately straight line), as well as a sparsely ionizing
penumbra generated by expelled electrons (where energy is
deposited throughout the material randomly).
In addition to differences in radiation quality, substrate com-
position is an important factor in radiation-induced damage.
To date, most radiation research has been conducted in biolog-
ical models, where a majority of the substrate is water. In this
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Figure 1. Factors limiting understanding of pharmaceutical stability in the space radiation environment. Radiation from galactic cosmic rays (GCR) is not
graphically depicted but should be considered ubiquitous in the space environment. PK/PD: Pharmacokinetics/Pharmacodynamics.
scenario, radiation is more likely to hit water than a biologi-
cally relevant target (e.g. DNA). However, even if radiation
impacts water rather than a target, it can still induce damage
to a target via generation of free radicals, which can diffuse
to interact and ionize a target within range. This form of
damage is known as indirect ionization, while damage caused
from radiation hitting a target is known as direct ionization.
In pharmaceuticals, where a greater percentage of substrate
composition consists of target molecules, direct ionization is
far more likely than in biological substrates. The difference
between percentage of target interactions that are direct ver-
sus indirect is highly dependent on substrate and projectile
energy.
It has been observed that direct ionization can cause in-
creased damage compared to indirect ionization, particularly
in the decomposition of chemical bonds, creation of radiolysis
products, and damage to polymer structure.8–10 Studies using
biological substrates therefore do not provide good analogues
for pharmaceutical research. Furthermore, clustered damage
imparted by densely ionizing space radiation combined with
the higher target concentration in pharmaceutical formularies
could potentially interact, resulting in outcomes that have not
yet been characterized.
Challenges in Reproducing Radiation
Dose, Dose-Rate, and Formulation Sensi-
tivity
Another area of uncertainty is the effect of low doses on
pharmaceuticals. Terrestrial pharmaceutical radiosterilization
techniques generally use doses of 25-50kGy, which far exceed
those expected for even cumulative Mars mission doses (ap-
proximately 0.5Gy). Delivery of radiosterilization doses over
a matter of minutes or hours considerably exceeds dose-rates
anticipated in interplanetary space, where such doses would
be accrued over 2-3 years by current estimates.
It has been suggested that, if a pharmaceutical is found to be
stable at higher doses or dose-rates (such as those provided by
radiosterilization techniques), then the pharmaceutical should
be stable at more limited exposures (such as those delivered in
space).11 Some evidence for this argument has been provided
by the expected level of damage from indirect ionization. De-
spite the relatively higher concentration of target molecules in
pharmaceutical than biological substrates, damage to pharma-
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ceuticals from indirect ionization does still occur, particularly
in liquid pharmaceuticals where target molecules are less
concentrated than in solid formulations. Indirect ionization-
induced damage stems from the formation of free radical
species; in water-based formulations, this includes the gener-
ation of radical oxygen species (oxygen ions and hydrogen
peroxide, H2O2) from the breakdown of water.12–14 Studies
have indicated that the concentration of these radicals from
exposures to radiosterilization doses (25-50kGy) is generally
well below toxic levels.15, 16 A recent NASA technical paper
indicated that nanomolar concentrations of radiation byprod-
ucts could be produced in exposed pharmaceuticals, but cited
low anticipated radiolytic yield in liquid-based pharmaceuti-
cals (based on modeled calculations) as sufficient evidence
that irradiated pharmaceuticals should be stable in the space
environment.11
However, even the low nanomolar concentrations of ions
predicted by that technical report could be enough to suf-
ficiently alter local pH in drug products, which could alter
chemistry or drive degradation reactions.18 In addition, stud-
ies using electron spin resonance, a sensitive method for the
detection of free radicals,19, 20 have demonstrated that alter-
ation of radiation dose changes the concentration and type of
free radicals produced, often with unpredicted complexity or
type of resultant radical species.20 These complex reactions
could alter subsequent radical-induced damage.20 Dose-rate
may be an important factor in the activity of radical species,
and many pharmaceuticals are demonstrated to be more stable
at higher dose-rates. It has been theorized that high dose-
rate increases oxygen consumption, resulting in decreased
presence of oxygen radicals (or the rapid consumption of
any radical species generated) and associated damage.16, 20
Shorter-duration exposures may produce fewer long-lived oxy-
gen radical species and, as a result, less prolonged opportunity
for delayed damage than protracted exposures. In evidence to
these arguments, one historical study of spaceflight-approved
pharmaceuticals compared drug stability at variable radiation
dose ranging from 0.1-50Gy and found drug degradation asso-
ciated with moderate radiation exposure where no instability
was noted at higher doses.17 It is worth reiterating that these
dose ranges include exposures that are substantially greater
than even cumulative anticipated doses in long-duration, ex-
ploration spaceflight.
Liquid pharmaceuticals are often considered less stable
than solid or powdered drugs given the greater potential for
free radical formation in water-based formulations, the pos-
sibility of interactions between substrate and excipients (the
pharmacologically inert compounds in a given dosage for-
mulation), incomplete dissolution of substrate, crystallization
of dissolved compounds, and other alterations of drug sus-
pensions over time. Water-based drugs will undergo more
frequent hydrolysis reactions, driving more prevalent and
more rapid degradation reactions. As a result, the rare discus-
sions of pharmaceutical stability in the context of space radia-
tion have focused on liquid formulations and postulated that,
should liquid formulations be determined to be stable in the
space radiation environment, solid or semi-solid formulations
would be of no additional concern.11 However, some studies
demonstrate radiation-induced instability in solid or powder
formulations, with reports of radical trapping in excipient lat-
tices leading to a longer presence of free radicals in powder or
solid drugs than in liquid formulations.21–24 In addition, the
interaction of particles with solid or powder substrates may
produce increased types and complexity of ion species due
to spallation. Spallation ions impacting stored pharmaceuti-
cals may cause increased direct and indirect ionizations or
induce additional chemical reactivity in the substrate. In short,
it is unclear how drugs of any formulation may respond to
the unique qualities of space radiation, simply because such
responses have not been studied to any degree of fidelity.
Given the uncertainty of drug response to alterations of
dose, dose-rate, or exposure time, radiosterilization is only
approved for well-documented procedures of declared dosage
(most commonly 25-50kGy) and dose-rate, and deviation from
the designated dose or dose-rate is assumed to be capable of al-
tering the final drug product.16, 20 In evidence to this concern,
the United States Pharmacopeia (USP) regards radiosterilized
pharmaceuticals as entirely new products, and pharmaceuti-
cal companies are required to submit new drug applications
and demonstrate safety, potency, and lack of toxic breakdown
products for approval of radiosterilization in any marketed
drug.16, 25 The use of terrestrial analog radiation to predict
the response of pharmaceuticals in the space environment di-
rectly contradicts the standard approach to safety and stability
review of irradiated pharmaceuticals. Finally, it should be
noted that many of the pharmaceuticals currently included in
a spaceflight formulary are not approved by the U.S. Food and
Drug Administration (FDA) for terrestrial radiosterilization
procedures.
Challenges in Emulating the Space Envi-
ronment
Accurate simulation of the complex space radiation environ-
ment for pharmaceutical testing via terrestrial analog is cur-
rently not possible, given limitations in radiation type and
dose-rate of exposure. Space radiation studies, pharmaceuti-
cal or otherwise, often make use of a recently updated GCR
simulator at the NASA Space Radiation Laboratory (NSRL)
at Brookhaven National Laboratory in Brookhaven, New York.
To date, the NSRL is the only U.S. government facility ca-
pable of generating heavy-charged particles at energies and
spectra that approximate the space environment.26, 27 Recent
improvements now allow for rapid switching between ion
species, providing rapid and consecutive exposures to dif-
ferent mono-energetic ion beams.26 Rapid switching of ion
beams may be sufficient in simulation of the complex space
environment, particularly as previous modeling has suggested
that the likelihood of multiple ion species traversing a small
volume at the same time (i.e. traversing a single drug tablet) is
exceedingly low.28 This rapid switching technique is a poten-
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Figure 2. NASA data from an NSRL study performed by L. Putcha demonstrating variable drug sensitivity to radiation exposure for clavulanate (as a
combination medication, amoxicillin-clavulanate) and promethazine.17 All drug products were measured at time-zero, control and irradiated products were
analyzed at the same time following exposures. The solid green line indicates USP-accepted lower limits of percent API content compared to label claims. Note
the variable sensitivity both by radiation beam exposure (proton, in red, or iron, in blue) and by dose received (0.1-50Gy). In this study, drugs demonstrated
increased degradation to 10Gy exposures compared to 50Gy exposures, suggesting that pharmaceutical stability at higher-dose exposure may not necessarily
translate to stability at lower-dose exposures. However, dose and dose-rate of high exposures were significantly greater than even cumulative anticipated doses
in long-duration, exploration spaceflight. Further, there is only limited documentation regarding research design or even the full results of this study, limiting
our ability to interpret findings.
tial improvement when compared to use of photon or single
ion exposures and offers more insight than studies with con-
siderably higher doses than those expected during spaceflight,
such as the doses used in radiosterilization literature.3, 26
However, even this simulator utilizes exposures that are
appreciably different from those anticipated in the interplane-
tary space environment, generally delivering cumulative an-
ticipated mission doses over short periods of time.26 While
the NSRL simulator is capable of providing more protracted
doses, limitations of funding for long-term experiments gen-
erally limit exposure times, causing deviation of the analog
from GCR. The simulator cannot generate the full spectrum
of ions or spallation ions that make up the GCR spectrum;
instead, exposures are limited to only a sampling of some
of the heavy ions that contribute to GCR, and these ions are
delivered sequentially rather than simultaneously. Further,
the simulator lacks the capacity to generate the pions (sub-
atomic particles) or neutrons that would follow spallation
reactions in the intravehicular environment,3, 27 though these
would be expected to account for 15-20% of an intravehicular
exposure.27, 29 These factors may limit ability to translate
terrestrial analog studies to an understanding of the true risk
of space radiation pharmaceutical exposure.
Even so, the NSRL simulator is one of the few simula-
tors available to study space-like radiation in the terrestrial
environment. To date, there are remarkably few studies of
pharmaceuticals at this facility. In 2011, Chuong et al. studied
the stability of solid formulations of vitamin B during space-
flight and in terrestrial radiation analogs, making use of an
older radiation simulator at the NSRL for some exposures.30
The authors studied vitamins that had flown onboard the Space
Shuttle and ISS for 2-4 weeks or 12-19 months, comparing
them to terrestrial controls and vitamins exposed to the terres-
trial radiation beam. While the NSRL exposures were used as
a terrestrial radiation study arm to examine radiation effects
on the vitamin, it is noteworthy that the NSRL exposures were
mono-energetic exposures of 0.1-50Gy, using either hydrogen
or iron radiation sources.30 The upper limits of exposures
in this study greatly exceed those expected during even long
duration and exploration spaceflight.
The USP allows variation of the active pharmaceutical
ingredient (API, the ingredient imparting the desired physi-
ological effect of a medication) within 90-150% of package
label content for vitamin B. The Chuong study did identify
statistically significant, though acceptable, variation in con-
tent of ground (unflown, non-irradiated) and NSRL irradi-
ated samples, and even identified one flown sample with API
concentration well below acceptable ranges.30 However, the
authors suggest that instability was most likely related to API
formulation, excipient interaction, or even packaging, and
stated that, since NSRL samples were found to be stable (at
notably higher dose-rate than flown samples), radiation was
not the cause of instability.30 As discussed above, this rea-
soning is questionable given the numerous factors that limit
translation of simulated radiation exposures to the true space
environment.
Additional research conducted at the NSRL by NASA on
numerous pharmaceuticals in an effort to delineate the effects
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of various radiation doses on drug stability similarly utilized
0.1-50Gy doses of proton or iron mono-energetic beams.17
Data released suggests dose-variable alterations of API, with
increased degradation noted at 10Gy exposures compared
with those at 50Gy exposures delivered over equivalent time
intervals (Figure 2).17 Study exposures are still notably higher
than those expected during spaceflight but suggest that sta-
bility at high-dose exposures may not necessarily translate to
stability at low-dose exposures, and that dose and dose-rate
alterations may significantly impact stability. Unfortunately,
there is only limited documentation regarding research design
or even the full results of this study, limiting our ability to
fully interpret findings.
Mechanisms of Pharmaceutical Instability
Pharmaceuticals can become unstable through alteration of
either their physical or chemical properties. Alteration of
physical properties includes changes in appearance or con-
sistency; alteration of chemical properties includes loss of
potency, alteration of excipients, excipient-active ingredient
interactions, or toxic degradation.31, 32 In order to determine
that a pharmaceutical is unchanged by exposure to the radi-
ation environment, a drug must be demonstrated following
exposure to have no significant alteration of its API(s) while at
the same time have no significant development of degradation
products that are either toxic themselves or in some way alter
the pharmaceutical properties of the original medication.18
The USP provides guidelines for acceptable API content in
medications approved by the FDA, commonly within 10%
of label-specified content (though this can vary considerably
by drug type or API).25 A medication would be considered
radiosensitive if API concentration fails to meet USP require-
ments following radiation exposure. Alterations of API can
affect drug potency, efficacy, and safety rendering the drug
less effective, ineffective, or potentially dangerous.
There are numerous documented cases of pharmaceuti-
cals being altered by radiation exposure at sterilization doses
(25-50kGy). For example, irradiation of metoclopramide
hydrochloride produced a number of degradation products fol-
lowing radiation exposure,33 and gamma sterilization of cer-
tain beta-blockers has been demonstrated to alter the pharma-
ceuticals’ color and appearance and affect the melting point of
the drug preparations.34 Even compounds that are molecularly
similar may have vastly different responses to irradiation.35
Cephradine and cefotaxime, both solid-form cephalosporin
antibiotics of similar molecular structure, demonstrate signif-
icantly different radiosensitivity when exposed to identical
sterilization doses of gamma radiation. Cephradine degrades
significantly and has been determined to be unstable under
irradiation36 where cefotaxime demonstrates high resistance
and stability.37, 38 As molecular alterations can change the
saturation of the compound or the presence or absence of re-
active groups such as alcohols, acids, or ketones, even minor
differences in API structure can affect radiosensitivity.
In addition to altering API, radiation exposure can result
in the generation of degradation products and may alter the
medication, whether or not the API is affected, by damaging
the structure or action of excipients. For example, radiation
is known to alter the chemical structure of various polymer
drug delivery systems, causing increased cross-linking of poly-
mers in some cases and inducing polymer chain breakage in
others.35, 39 Cross-linked polymers, with higher molecular
weight, may cause issues with insolubility,40 and chain break-
age of some polymeric microspheres used for drug delivery
have been associated with high production of free radicals
and instability of the resultant compounds.35, 41 In some stud-
ies, alteration of excipients has been demonstrated to affect
dissolution rates and controlled release of API.42, 43
Radiosensitivity is highly specific to dose, dose-rate, radi-
ation type (photon, electron, proton, heavy ion, etc), chem-
ical composition, excipient content, and drug formulation.
However, it must also be stated that any radiation-induced
pharmaceutical risk must be weighed in the context of the
multitude of other factors that may render a flown drug un-
stable in the space environment. Mission duration will soon
extend beyond approved shelf life for many medications cur-
rently included in onboard medical kits. Current medications
aboard the ISS are replenished through regular resupply and
removal of older drugs; this may not be possible with future
missions to the moon or Mars.18 Older drugs may be at higher
risk of degradation from chronic exposure to the radiation
environment.
NASA currently repackages some of the flown pharmaceu-
ticals to manage mass and volume constraints and to limit
packaging waste in the closed environment of a space ve-
hicle. However, repackaging itself may affect shelf life or
stability of stored medications or alter their response to ra-
diation exposure.18, 44 For example, nuclei interacting with
packaging material could produce additional progeny ions that
alter the chemical composition of pharmaceuticals within.31
Previous studies have suggested various packaging materials
that may be intrinsically better for radiation shielding, such
as polyethylene;31, 45–47 however, there are insufficient data
regarding ideal packaging technique or long-term shelf life of
pharmaceuticals packaged in such materials, and any novel
packaging approach intended for use onboard future missions
would be subject to USP review and guidelines.25 Ultimately,
choice of packaging materials should address radiation sensi-
tivity as well as additional shelf life concerns, particularly as
it remains unclear how the factors of drug age, repackaging,
shelf life, and radiation exposure will interact to determine
pharmaceutical response.
There have been very few examinations of pharmaceuti-
cals actually exposed to the space environment, including
a ground-controlled study of API in flown pharmaceuticals
conducted by Du et. al.49 and a convenience sampling of
pharmaceuticals returned to Earth after ¿550 days aboard
the ISS by Wotring (see Figure 3).48 More recently, Cory
et. al.51 and Wu et. al.52 sought to analyze potency, pu-
rity, and drug degradation in certain pharmaceuticals flown
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API and Physical Characteristics
Acyclovir
Amoxicillin/Clavulanate
Atorvastatin
Azithromycin
Cefadroxil
Ciprooxacin
Clotrimazole
Dextroamphetamine
Epinephrine
Fluconazole
Furosemide
Ibuprofen
Imipenem/Cilastin
Levooxacin
Levothyroxine
Lidocaine
Metoprolol
Metronidazole
Mupirocin
Nasal Cobolamine
Phenytoin
Progestin/Estrogen
Promethazine
Risedronate
Sertraline
Silver Sulfadiazine
Sulfamethoxazole/
         Trimethoprim
Temazepam
Triamcinolone
Centrum Silver® Multivitamin*
Women’s Once-A-Day® Multivitamin*
Aspirin
Acetaminophen**
Ibuprofen
Loratadine** †
Loperamide †
Pseudoephedrine
Melatonin 
Modanil †
Zolpidem †
13 Days
354 Days
597 Days
881 Days
Variable 
  Exposure 550 Days
Variable 
  Exposure
API (B Vitamin only) API, 
Degradants 
Unpublished
Results
Ground Control Available
Unpublished
Results
Variable 
  Exposure
Ibuprofen
Levooxacin
Phenytoin
Sertraline
Valacyclovir
Ibuprofen
Promethazine
Azithromycin
13 Days
353 Days
596 Days
880 Days
Centrum Silver® Multivitamin •
Vitamin D Supplement •
API
Radiation Arm
Figure 3. To date, there have been few studies of pharmaceuticals flown in the space environment. The studies presented in the figure included various
evaluations of active pharmaceutical ingredient (API), physical characteristics, impurity products, and degradation, as indicated.30, 48–52 Only one study by
Chuong et. al.30 included ”radiation arm,” a subset of ground controls that were irradiated with either hydrogen or iron ions at high dose and dose-rate dissimilar
to the space environment. Drugs in red text were found to have alterations of API, physical characteristics, or contain significant concentrations of degradants
or impurities after flight in one or more preparation of the indicated pharmaceutical. *Multivitamin preparations were analyzed only for B-complex API
stability. **Drugs contained API concentrations within acceptable limits at time of study analysis, but would fail API analysis according to current standards.
†Drugs contained unspecified or unidentified impurity products of unknown significance. •Multivitamin content demonstrated time-related instability but
showed no alteration specifically related to spaceflight exposure.
aboard the ISS, though these results have yet to be published.
Two additional papers addressed multivitamin stability after
spaceflight exposure, including Chuong et al.30 and Zwart
et al.50 In general, most pharmaceuticals tested after flight
have been found to meet USP requirements for API concen-
tration, though notable exceptions occurred. For example,
Du et. al. found that amoxicillin-clavulanate, levofloxacin,
trimethoprim, sulfamethoxaxole, furosemide, and levothyrox-
ine degraded before their expiration dates.18, 49 The study
additionally identified alterations of physical appearance of
some medications. Wotring identified degradation and impu-
rity products in aspirin, ibuprofen, loratadine, modafinil, and
zolpidem.48 The two multivitamin studies identified alteration
of multivitamins over time in both ground and flown samples
when compared to time-zero controls, but neither found con-
vincing evidence of degradation specific to spaceflight-flown
formulations.30, 50 While these studies have provided at least
some much-needed pilot data, they are limited by the ability
to provide adequate ground-control, control of confounders,
or appropriate reproducibility given limited sample size, and
can provide only an initial awareness that flown pharmaceuti-
cals may not be stable in the space environment. It is worth
emphasizing that pilot data do suggest that expected radia-
tion exposures may be sufficient to affect medication stability.
While yet unpublished, reported results from more recent ex-
periments performed by Cory et. al. and Wu et. al. were
similarly limited by exposure-time variables, limited ground
controls, and drug lot variability, but again suggest instability
despite theoretical expectations to the contrary.51, 52
Finally, despite decades of pharmaceutical use in space-
flight, there is limited knowledge regarding alterations of
pharmacokinetics (absorption, metabolism, and excretion of
a medication) and pharmacodynamics (drug effects on the
body) in the space environment. As the human body under-
goes significant physiological and metabolic changes during
spaceflight, it stands to reason that the effects of pharmaceu-
ticals on an astronaut may change during flight.53 However,
research on this issue has largely been limited to observational
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reports and analog studies.18, 53 Without directed studies to
examine the multifactorial impact of the space environment
on pharmaceutical response, it is difficult to fully understand
how the additional risks from space radiation may further alter
drug response, if at all, during exploration missions.
Discussion
Numerous confounders, limited spaceflight studies, and chal-
lenges in translation of terrestrial analog evidence to space-
flight have all hindered our ability to draw meaningful con-
clusions regarding the stability of pharmaceuticals during
exploration spaceflight. As NASA looks towards the chal-
lenges associated with missions involving increased distance
from Earth, the current inability to provide a safe and effective
pharmacy for exploration spaceflight has been identified as a
major research gap.54 To address this issue, NASA recently
developed a Pharmacy Research Plan in which pharmaceuti-
cal stability and radiation risk are highlighted as unknowns
that should be addressed in dedicated research efforts prior
to lunar or Mars missions.55 However, this research plan
faces challenges including approaching mission design-freeze
deadlines and a need to declare a planned formulary for fast-
approaching exploration missions, expected to occur within
the next decade of spaceflight.
As an adjunct to NASA’s research plan, recent literature has
provided potential solutions for storage- and radiation-related
stability concerns. For example, there has been some sugges-
tion that cryogenic storage conditions may be protective to
pharmaceuticals during spaceflight.31, 56 Such methods have
been demonstrated to be successful during radiosterilization
processes, providing increased stability of medications during
gamma or x-ray exposure.31, 57, 58 Even so, some formulations
may demonstrate decreased stability with freezing; for many
drugs, effects are unknown or unstudied. There have been no
studies of cryogenically stored pharmaceuticals exposed to
space-like radiation doses, dose-rates, or spectral complexity.
It is difficult to predict the response of cryogenic pharma-
ceuticals to the space environment, given the multitude of
confounding factors and the paucity of data available.
Similarly, previous literature has discussed the potential
inclusion of ”space-hardy” formulations, such as use of excipi-
ents believed to be more stable in a radiation environment.31, 48
For example, formulations including starch, stearate, cellu-
lose, and dextrose may be more likely to be stable than alterna-
tives, based on results from the 2016 Wotring study31, 48 Other
options include preparations including excipients such as man-
nitol, nicotinamide, and pyridoxine, which have demonstrated
radioprotective properties in terrestrial sterilization process-
ing.31 A more thorough discussion of potential excipients for
improved stability, radioprotective qualities, and antioxidant
effects can be found in Mehta et al.31 However, it should be
reiterated that much of the literature supporting inclusion or
exclusion of excipients for protective or stability properties
is again based on incomplete data, convenience sampling, or
radiation exposures dissimilar to the space environment, lim-
iting the translation of findings particularly for long-duration,
exploration missions. Further, altering or adding excipients
would change drug formulation; the resultant product would
be considered a new drug and, per USP regulations, would
require a new application for drug approval and demonstration
of safety, potency, and lack of toxic breakdown products.
Finally, there has been discussion of limiting the impact of
pharmaceutical irradiation through the inclusion of onboard
shielding.56 In collaborative efforts to protect human crew
from radiation exposure, there has been much discussion re-
garding the inclusion of a heavily-shielded compartment of
thick aluminum or other radioprotective material, or alter-
natively by the use of ”multi-purpose shielding solutions,”
such as barriers composed of water or food supplies, on ex-
ploration vehicles.56, 59, 60 Pharmaceuticals could be stored
within a shielded compartment to reduce radiation exposures.
While these innovative efforts show promise, it is important to
remember that shielding designs may be limited by mass and
volume constraints and lift-mass capabilities of the launching
vehicle. It is premature to assume that idealized shielding will
be successfully implemented in early exploration vehicles.
Many of the shield designs are intended for ”just-in-time”
deployment for protection of crew;60 in such circumstances,
crew would have to retrieve onboard pharmacy stores and
transfer them into the shielded space to protect drugs from
SPEs. Even if a high degree of shielding were to be imple-
mented, such a compartment would only mitigate transient
exposures associated with large SPEs, and protracted expo-
sure to GCR would continue to pose a threat to drug stability
in long-duration spaceflight.
Ultimately, successful mitigation of radiation risk relies
upon a more thorough understanding of the potential effects
of radiation upon pharmaceuticals, insight regarding which
pharmaceuticals are at highest risk for radiation-induced dam-
age, and an awareness of how the myriad of spaceflight-related
factors (e.g. altered pharmacokinetics and pharmacodynam-
ics, radiation dose, radiation dose-rate, packaging, shelf life,
etc.) affect an exposed drug. Careful and controlled study of
pharmaceutical stability, with ground controls and appropriate
sample size, would greatly improve our understanding of the
multifactorial risks to pharmaceuticals in space. Additional
ground-based studies comparing the effects of gamma, x-ray,
or electron beam to proton or heavy ion exposure may improve
understanding of how to better translate terrestrial literature
to the context of space radiation. Utilization of the ISS as a
research platform, with long-duration storage of pharmaceu-
ticals and well-designed and controlled studies of shelf life
and radiation exposure, could provide much-needed under-
standing of stability in actual spaceflight conditions. However,
such studies would need to be initiated rapidly, as the ISS is
intended for decommissioning within the next decade. With
rapidly approaching exploration mission dates, NASA and its
international partners seek a mature pharmaceutical formulary
that can be realized before vehicle and mission design freezes
occur. Inclusion of pharmaceuticals (particularly novel or
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complex pharmaceuticals not currently included in the ISS
formulary) onboard future manned or unmanned missions
outside of LEO could provide additional data of drug stability
in the actual deep-space environment; however, most of these
missions do not return payloads to the Earth, limiting analysis
options. Maximizing analysis opportunities requires program-
matic commitments to sample return; this in turn depends
upon an increased understanding of the importance of these
data.
As a comprehensive research plan onboard the ISS may
not be feasible given time and financial constraints, study of
comparative effects of single- and multi-energetic exposures
may improve our understanding of the complexity of the space
radiation environment and its impact on pharmaceuticals. As
discussed above, use of dose and dose-rates that more closely
emulate the space environment may provide more useful or
accurate results than reliance upon high dose and dose-rate ex-
posures. Further, inclusion of shielding materials in terrestrial
analog design, to both mitigate dose and simulate potential
spallation reactions, may better mimic the ionic composition
of the intravehicular environment.29 Comparative studies of
drugs both including and excluding shielding or packaging ma-
terials may provide insight regarding the relative contribution
of such materials to pharmaceutical degradation reactions.
Careful and thorough evaluation of pharmaceuticals ex-
posed to the space environment is overdue, and the paucity
of data limits appropriate translation of terrestrial studies for
understanding of space radiation exposures. It is critical to
address these knowledge gaps before missions to the moon or
Mars are underway. There are significant advances that can be
achieved by a well-planned research effort that provides both
actual flight data from flown pharmaceuticals aboard available
research platforms, such as the ISS, as well as translational
studies of comparative effects of space-like radiation in ter-
restrial analogs, allowing for better interpretation of historical
terrestrial radiation understanding in the context of space-
flight. Use of improved and robust modeling techniques that
better emulate the space environment, careful study of various
formulations, alternate drug choices, and packaging materi-
als, and consideration of novel techniques, such as cryogenic
storage, could provide much-needed advances towards the
development of a pharmaceutical capability for interplanetary
flight.
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